NewEdge Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
Other funds holding JAZZ
NewEdge Advisors's JAZZ Position: Q2 2026 in Review
NewEdge Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 16% in Q2 2026, buying an estimated $67.9K and bringing the position to 2,285 shares worth $551K. The position accounts for ﹤0.01% of the portfolio, ranked #2082.
NewEdge Advisors first reported a position in JAZZ in Q2 2017 and has held it in 19 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- NewEdge Advisors held 2,285 shares of Jazz Pharmaceuticals worth $551K as of Q2 2026.
- NewEdge Advisors bought 310 Jazz Pharmaceuticals shares in Q2 2026, an estimated $67.9K.
- Jazz Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2082 holding.
- NewEdge Advisors first reported a position in Jazz Pharmaceuticals in Q2 2017 and has held it in 19 quarters since.
- 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.